Strategic Partnership with RedHill Biopharma
Cumberland entered into a partnership with RedHill Biopharma to commercialize Talicia, an FDA-approved treatment for helicobacter pylori infections, showing a high eradication rate exceeding 90%.
International Expansion
Cumberland launched Vibativ in Saudi Arabia and received regulatory approval for ibuprofen injection in Mexico, expanding its international footprint.
Strong Revenue Growth
Year-to-date revenue grew 12% over the same period last year, with total revenues reaching $30.9 million for the first nine months of 2025.
Positive Cash Flow
Cumberland reported a positive cash flow from operations, amounting to $5 million through September 2025.
Ifetroban Clinical Progress
Positive top-line results from the FIGHT DMD trial for ifetroban in Duchenne muscular dystrophy were reported, showing significant improvements in cardiac function.